# HTL Biotechnology

> HTL Biotechnology is a VC fund in Javené backing Health Care and Biotechnology. See 2 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Javené, France
- Total investments: 2
- Last investment: Feb 2026
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/htl-biotechnology/
- Website: http://www.htl-bio.com

HTL Biotechnology is a VC fund in Javené focused on Health Care and Biotechnology. HTL is a manufacturer and research & development of Hyaluronan and other biological polymers by bacterial fermentation.HTL SAS was created in 1992 and is specialized in the manufacture, purification and research and development of Hyaluronan (HA). Today it has diversified and produces other biological polymers (see new products) for thepharmaceutical and medical fields.

## Contacts

5 contacts available for HTL Biotechnology. Shizune tracks 4 team members at HTL Biotechnology. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/htl?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 100% |
| Biotechnology | 2 | 100% |
| Medical Device | 1 | 50% |
| Pharmaceutical | 1 | 50% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 1 | 50% |
| United States | 1 | 50% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Cyril Picault | Chief Operating Officer | 0 | — |
| Glenn Prestwich | Science & Innovation Advisor | 0 | — |
| Susanne Liepmann | Group CFO | 0 | — |
| Yvon Bastard | Chief Executive Officer & Président-Directeur Général | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Gelmedix | Gelmedix is a developer of a biomaterial platform to improve drug delivery for complicated ophthalmic treatment. The company's platform offers a single non-invasive gel patch that can be used as a drug-eluting sealant with tissue adhesion, tunable drug elution, and biocompatibility properties, thereby enabling healthcare providers to reducethe usage of drops which cause inconvenience to patients. | $13M | Seed | Feb 17, 2026 |  |
| BIOPHTA | BIOPHTA has pioneered a new approach to eye care by creating a cutting-edge pharmaceutical platform that enables continuous drug delivery. Their non-invasive topical ocular inserts represent a significant advancement in the treatment of many ophthalmic disorders, providing superior long-term disease management. | $7.1M | Seed | Jun 03, 2024 |  |

2 of 2 investments shown.

## Co-investors
- [Safar Partners](https://shizune.co/investors/profile/safar-partners-7ab4) — VC Fund, 2 deals together
- [Beacon Angels](https://shizune.co/investors/profile/beacon-angels) — VC Fund, 1 deal together
- [Boston Harbor Angels](https://shizune.co/investors/profile/boston-harbor-angels) — VC Fund, 1 deal together
- [Elaia](https://shizune.co/investors/profile/elaia-partners) — VC Fund, 1 deal together
- [GO CAPITAL](https://shizune.co/investors/profile/ouest-ventures) — VC Fund, 1 deal together
- TiE Angels Boston — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does HTL Biotechnology invest in?

HTL Biotechnology invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Seed stage. Most of the 2 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact HTL Biotechnology?

Public channels for HTL Biotechnology include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at HTL Biotechnology?

The team at HTL Biotechnology includes Cyril Picault (Chief Operating Officer), Glenn Prestwich (Science & Innovation Advisor) and Susanne Liepmann (Group CFO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co